Engineering Halomonas sp.
By overexpressing the porin58 promoter in Saltmonas, the ureA gene was regulated, the problem of ammonia release during Saltmonas fermentation was solved, the utilization rate of urea and PHA yield of Saltmonas was improved, and the higher cell accumulation density and lower ammonia emissions.
Patent Information
- Application Number
- CN202411318626.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-22
AI Technical Summary
In the process of fermenting and producing polyhydroxy fatty acid ester by Saltmonas fermentation, urea hydrolyzes into ammonium ions and releases ammonia, resulting in unfavorable growth of Saltmonas . The existing high-ventilation method has wasted energy consumption and decreased PHA production question.
By overexpressing the porin58 promoter in Saltmonas, ureA gene is regulated, and urea utilization is improved and ammonia emissions are reduced.
Higher cell accumulation density, higher product content and lower ammonia emissions are achieved, and the utilization rate of salmonas on substrates is improved.
Smart Images

Figure BDA0005052948630000061
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of biomaterials, and in particular to an engineered Halomonas bacterium and a construction method thereof, and a method for producing polyhydroxyalkanoates using the same. Background Art
[0002] Halomonas sp. is a moderately halophilic bacterium isolated from Xinjiang Aidin Salt Lake. It can synthesize polyhydroxyalkanoates (PHA), which is a naturally degradable polyester and is considered one of the most preferred biodegradable materials to replace petroleum-based materials. Therefore, in the current context of promoting green manufacturing, PHA has a very considerable development potential.
[0003] In the process of producing PHA by fermentation of Halomonas, urea is used as a nitrogen source, which is hydrolyzed and converted into ammonium ions under biological transformation and spontaneous action. The ammonium ions are further released in the form of ammonia under alkaline warm conditions, which has an adverse effect on the growth of Halomonas. Under existing process conditions, a large amount of ammonia will be released during the fermentation process, especially when the microbial growth is poor and the urea in the substrate cannot be used in time. This situation is particularly serious. The related art uses a high ventilation method to remove ammonia from the fermentation system. However, this method has the disadvantages of energy waste and reduced PHA production.
[0004] Therefore, there is an urgent need to develop an engineered Halomonas that can efficiently utilize substrates to ferment and produce PHA, and a method for producing PHA using the same. Summary of the invention
[0005] The present invention solves one of the problems of the related art from at least the following aspects.
[0006] The first aspect of the present application provides an engineered Halomonas, in which a first gene is overexpressed by a first promoter, wherein the first promoter is porin58, and the first gene is ureA.
[0007] In some embodiments, the nucleotide sequence of the first promoter is shown in SEQ ID: 1.
[0008] In some embodiments, the nucleotide sequence of the first gene is shown in SEQ ID: 2.
[0009] In some embodiments, the Halomonas is selected from Halomonas bluephagenesis and / or Halomonascampaniensis.
[0010] In some embodiments, the Halomonas is selected from the group consisting of Halomonasbluephagenesis TD01, Halomonas campaniensis LS21, and Halomonas bluephagenesisWZY254.
[0011] In some embodiments, the engineered Halomonas is Halomonas bluephagenesis TD01-porin58-ureA, Halomonas campaniensis LS21-porin58-ureA, or Halomonas bluephagenesis WZY254-porin58-ureA.
[0012] The second aspect of the present application provides a method for constructing an engineered Halomonas according to any one of the first aspects, including: overexpressing a first gene in Halomonas through a first promoter.
[0013] In some embodiments, overexpressing a first gene in Halomonas via a first promoter comprises:
[0014] Inserting the first promoter and the first gene into a first vector to obtain a first plasmid;
[0015] The first plasmid is transformed into the Halomonas by conjugation.
[0016] In some embodiments, the first vector is pSEVA321.
[0017] The third aspect of the present application provides a method for producing polyhydroxyalkanoates, comprising: using the engineered Halomonas according to any of the first aspect embodiments to ferment and produce polyhydroxyalkanoates.
[0018] In some embodiments, the nitrogen source of the fermentation medium of the engineered Halomonas comprises urea.
[0019] In some embodiments, the initial content of urea in the fermentation medium is 0.3 to 0.8 g / L, preferably 0.5 g / L.
[0020] In some embodiments, the polyhydroxyalkanoate is selected from the group consisting of: 3-hydroxybutyric acid homopolymer PHB, 3-hydroxybutyric acid and 4-hydroxybutyric acid copolymer P3HB4HB, 3-hydroxybutyric acid, 4-hydroxybutyric acid and 3-hydroxyvaleric acid terpolymer PHBV4HB, 3-hydroxybutyric acid and 3-hydroxyhexanoic acid copolymer PHBHHx, 3-hydroxypropionic acid homopolymer, and 3-hydroxypropionic acid copolymer,
[0021] The homopolymer of 3-hydroxypropionic acid is P3HP, and the copolymer of 3-hydroxypropionic acid is P(3HB-co-3HP) or PHBHP.
[0022] Compared with the related art, the embodiments of the present application achieve at least the following beneficial effects:
[0023] In the engineered salt mononas provided in the examples of the present application, by overexpressing the first gene through the first promoter, the utilization rate of the substrate (urea) by the engineered salt mononas is significantly improved, and a higher cell accumulation density, a higher product content and a lower ammonia emission can be achieved simultaneously. DETAILED DESCRIPTION
[0024] The present invention is further described in detail below in conjunction with specific embodiments. The examples provided are only for illustrating the present invention and are not intended to limit the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art and are not intended to limit the present invention in any way.
[0025] In the present invention, the term "comprising" is an open expression, that is, including the contents specified in the present invention, but not excluding other contents.
[0026] This application is made based on the following knowledge of the inventor:
[0027] In the process of producing PHA by fermentation of Halomonas, urea is used as a nitrogen source, which is hydrolyzed and converted into ammonium ions under biological transformation and spontaneous action. The ammonium ions are further released in the form of ammonia under alkaline warm conditions, which has an adverse effect on the growth of Halomonas. Under existing process conditions, a large amount of ammonia will be released during the fermentation process, especially when the microbial growth is poor and the urea in the substrate cannot be used in time. This situation is particularly serious. The related art uses a high ventilation method to remove ammonia from the fermentation system. However, this method has the disadvantages of energy waste and reduced PHA production.
[0028] The applicant has found through a large number of experiments that overexpressing a first gene (e.g., the structural gene ureA in the urease gene cluster from Halomonas) through a first promoter can significantly improve the utilization rate of the substrate (urea) by Halomonas, and can simultaneously achieve a higher cell accumulation density, a higher product content, and a lower ammonia emission.
[0029] The first aspect of the present application provides an engineered Halomonas, in which a first gene is overexpressed by a first promoter, wherein the first promoter is porin58, and the first gene is ureA.
[0030] In some embodiments, the nucleotide sequence of the first promoter is shown in SEQ ID: 1.
[0031] tcccagtatatatttgac (SEQ ID NO: 1).
[0032] In some embodiments, the nucleotide sequence of the first gene is shown in SEQ ID: 2.
[0033] atggaactgaccccacgagacaaagataagctgctgctgttttctgctgcccagcttgccgagcgccgcaaagcacgcggcctaaagcttaactaccccgaagccgtggcgctgatcagcttcgaaattatcgaaggcgcccgtgacggcaga agtgttgccgacttaatgagctacggtcgtgaaatccttagccgtgatgacgtcatggatggcgtggcggaaatggtggatgaggtgcaggtagaagccacctttccggatggcaccaagctcgtgaccgttcacacgccaatcaactag(SEQ ID NO:2).
[0034] In some embodiments, the Halomonas is selected from Halomonas bluephagenesis and / or Halomonascampaniensis.
[0035] In some embodiments, the Halomonas is selected from the group consisting of Halomonasbluephagenesis TD01, Halomonas campaniensis LS21, and Halomonas bluephagenesisWZY254.
[0036] Bacteria used in the examples of this application:
[0037] Halomonas bluephagenesis TD01, the strain was deposited in the General Microbiological Center of China Microorganism Culture Collection Administration on November 19, 2010, with the deposit registration number of CGMCC No.4353, and the classification name is Halomonas sp.TD01 (also known as Halomonas bluephagenesis TD01; it is recorded in the patent application publication number CN102120973A, and the public can also obtain the strain from Tsinghua University.
[0038] Halomonas campaniensis LS21: It is a Gram-negative halophilic bacterium screened by our laboratory. It has very good prospects for industrial production and application. The public can obtain this bacterium from Tsinghua University. It is disclosed in Chinese patent CN115927137A, with the deposit number CGMCC No.6593.
[0039] Halomonas bluephagenesis WZY254 strain (TDH4ΔphaP1,ΔlpxL,ΔlpxM,P Mmp1 -phaCAB was replaced with P porin -phaCAB) was prepared from the starting strain Halomonas bluephagenesisTDH4 by knocking out the phaP1 gene, lpxL gene, and lpxM gene, and using P porin -phaCAB replaces P Mmp1 -phaCAB, for details, refer to the literature: Wang, Ziyu et al. "Hyperproduction of PHA copolymers containing high fractions of 4-hydroxybutyrate (4HB) by outer membrane-defected Halomonas blue phagenesis grown in bioreactors." Microbial biotechnology.
[0040] The construction of Halomonas bluephagenesis TDH4 strain is described in Shen R, Yin J, Jian-WenYe et al. (Promoter Engineering for Enhanced P(3HB-co-4HB) Production by Halomonas bluephagenesis [J]. ACS Synthetic Biology, 7(8): 1897-1906). The public can also obtain the strain from Tsinghua University.
[0041] In some embodiments, the engineered Halomonas is Halomonas bluephagenesis TD01-porin58-ureA, Halomonas campaniensis LS21-porin58-ureA, or Halomonas bluephagenesis WZY254-porin58-ureA.
[0042] It can be understood that Halomonas bluephagenesis TD01-porin58-ureA is an engineered strain obtained by overexpressing ureA through porin58 in Halomonasbluephagenesis TD01 as a starting strain; Halomonas campaniensis LS21-porin58-ureA is an engineered strain obtained by overexpressing ureA through porin58 in Halomonas campaniensis LS21 as a starting strain; Halomonasbluephagenesis WZY254-porin58-ureA is an engineered strain obtained by overexpressing ureA through porin58 in Halomonas bluephagenesis WZY254 as a starting strain.
[0043] The second aspect of the present application provides a method for constructing the engineered Halomonas described in any embodiment of the first aspect, comprising: overexpressing a first gene in the Halomonas through a first promoter.
[0044] In some embodiments, the overexpression of a first gene in Halomonas via a first promoter comprises: inserting the first promoter and the first gene into a first vector to obtain a first plasmid; and transforming the first plasmid into the Halomonas via conjugation.
[0045] In some embodiments, the first vector is pSEVA321.
[0046] The third aspect of the present application provides a method for producing polyhydroxyalkanoates, comprising: using the engineered Halomonas described in any of the embodiments of the first aspect to ferment and produce polyhydroxyalkanoates.
[0047] In some embodiments, the nitrogen source of the fermentation medium of the engineered Halomonas comprises urea.
[0048] In some embodiments, the initial content of urea in the fermentation medium is 0.3 to 0.8 g / L (eg, 0.4 g / L, 0.5 g / L, 0.6 g / L, 0.7 g / L).
[0049] In some embodiments, the initial content of urea in the fermentation medium is 0.5 g / L.
[0050] The fermentation method used in the embodiments of the present application is a conventional fermentation method using urea as a nitrogen source. As an example, the specific formula of the MM culture medium used to cultivate halophilic microorganisms in the embodiments of the present application is as follows: 0.5 g / L urea; 0.2 g / L MgSO4; 1.5 g / L KH2PO4; and 0.05 g / L Fe(III)-NH4-Citrate (ammonium iron (III) citrate), 0.02 g / L CaCl2·2H2O, 0.1 mg / L ZnSO4·7H2O, 0.03 mg / L MnCl2·4H2O, 0.3 mg / L H3BO3, 0.2 mg / L CoCl2·6H2O, 0.01 mg / L CuSO4·5H2O, 0.02 mg / L NiCl2·6H2O, and 0.03 mg / L NaMoO4·2H2O.
[0051] The aforementioned MM medium was used as the basal medium, and 20 g / L of glucose and 10 g / L of sodium chloride were added to conduct a fermentation tank experiment. This time, a 7L fermentation tank was used, the fermentation liquid volume was 3L, the pH was set at 9.0, and the temperature was maintained at 37°C. A major advantage of halophilic fermentation is that it can be open fermented without additional sterilization. At the same time, various air filters and complex aseptic operations are not required during the fermentation process to reduce the possibility of contamination, which greatly saves production costs and manpower and material resources. Conventional open fermentation relies on a high-salt and high-pH environment to inhibit the growth of other bacteria. Glucose 30 g / L was added to the culture medium as a carbon source, and 5-100 g / L of sodium chloride was added to provide the osmotic pressure environment required for the growth of halophilic bacteria; and the pH was adjusted to 9.0.
[0052] In some embodiments, the polyhydroxyalkanoate is selected from the group consisting of: a 3-hydroxybutyric acid homopolymer PHB, a 3-hydroxybutyric acid and 4-hydroxybutyric acid copolymer P3HB4HB, a 3-hydroxybutyric acid, 4-hydroxybutyric acid and 3-hydroxyvaleric acid terpolymer PHBV4HB, a 3-hydroxybutyric acid and 3-hydroxyhexanoic acid copolymer PHBHHx, a homopolymer of 3-hydroxypropionic acid, and a copolymer of 3-hydroxypropionic acid, wherein the homopolymer of 3-hydroxypropionic acid is P3HP, and the copolymer of 3-hydroxypropionic acid is P(3HB-co-3HP) or PHBHP.
[0053] The following examples are used to further illustrate the advantages and characteristics of the present method, but are not intended to limit the present invention. The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions.
[0054] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in the art (e.g., reference to "Molecular Cloning Experiment Guide" by J. Sambrook, etc., translated by Huang Peitang, etc., the third edition, Science Press) or the product instructions are followed. The reagents or instruments used that do not indicate the manufacturer are all conventional products that can be obtained commercially.
[0055] Unless otherwise specified, the quantitative analysis experiments in the following examples were performed three times and the results were averaged.
[0056] The method for detecting PHA content by gas chromatography in the embodiment of the present application is as follows:
[0057] The oven temperature was set at 80°C, the injector temperature was set at 200°C, the detector temperature was set at 220°C, the column head pressure was set at 0.25 MPa, and the program temperature was set as follows: stay at 80°C for 1.5 minutes, increase the temperature to 140°C at a rate of 30°C / min, and then increase the temperature to 220°C at a rate of 40°C / min and keep at this temperature for 0.5 minutes. The sample injection volume was 1 μl, and a microinjector produced by Agilent was used.
[0058] Preparation of gas phase samples: Take 40-60 mg of dry cells of the sample to be tested (take the bacterial solution and centrifuge it at 10000 rpm at room temperature for 10 minutes, wash the obtained cell precipitate with water once, and then freeze-dry to obtain dry cells. Homopolymers are produced in cells), add 2 ml of chloroform and 2 ml of esterification solution (pure methanol containing 3% (v / v) concentrated sulfuric acid and 1 g / L benzoic acid as internal standard) in an esterification tube, cover and seal it, and heat it at 100°C for 4 hours. After cooling, add 1 ml of distilled water, shake it thoroughly and let it stand. After the chloroform phase and the water phase are completely separated, take 1 μl of the lower chloroform phase and inject it into a gas chromatograph (HP Hewlett Packard 6890) for chromatographic analysis. Operate the gas chromatograph according to the instructions of the HP Hewlett Packard 6890 gas chromatograph.
[0059] Preparation of standard samples: Take 10-20 mg of standard sample into an esterification tube, add 2 ml of chloroform and 2 ml of esterification liquid, cover and seal, and then esterify at 100°C.
[0060] Result analysis: Taking the standard sample as the control, if the esterified sample of the cells to be tested (the sample to be tested) has an obvious peak at the standard sample, the mass of each monomer can be calculated based on the peak area, and then the molar ratio can be calculated based on the mass fraction of each monomer; the proportion of polymers contained in the cell dry weight (wt%) can be calculated based on the amount of sample added.
[0061] The cell dry weight (CDW, g / L) mentioned in the examples of the present application is the ratio of the mass of the dry cells to the volume of the fermentation product. The PHA content (wt%) mentioned in the examples of the present application is the mass ratio of P3HB to the dry cells.
[0062] Example 1
[0063] 1.1 Overexpression of ureA in Halomonas bluephagenesis TD01
[0064] The promoter porin58 sequence (SEQ ID NO: 1) and the ureA gene fragment (SEQ ID NO: 2) were inserted into the vector pSEVA321 to obtain the plasmid pSEVA321-pPorin58-ureA, which was then transformed into Halomonas bluephagenesis TD01. The resulting engineered Halomonas was named Halomonas bluephagenesis TD01-porin58-ureA.
[0065] 1.2 Fermentation production of PHA
[0066] Halomonas bluephagenesis TD01 and Halomonas bluephagenesis TD01-porin58-ureA were used to produce PHA by fermentation, and the cell dry weight, PHA content and ammonia concentration in the tail gas after fermentation are shown in Table 1 below.
[0067] Table 1
[0068] strains Cell dry weight PHA content Ammonia concentration in tail gas TD01 86.10g / L 80% 0.3%(v / v) TD01-porin58-ureA 95.11g / L 81% 0.01%(v / v)
[0069] According to Table 1 above, overexpression of ureA in Halomonas bluephagenesis TD01 can simultaneously achieve higher cell accumulation density, higher product content and lower ammonia emissions.
[0070] Example 2
[0071] According to the same manner as in Example 1, ureA was overexpressed in Halomonas campaniensis LS21, and the resulting engineered Halomonas was named Halomonas campaniensis LS21-porin58-ureA.
[0072] Halomonas campaniensis LS21 and Halomonas campaniensis LS21-porin58-ureA were used to produce PHA by fermentation, and the cell dry weight, PHA content and ammonia concentration in the tail gas after fermentation are shown in Table 2 below.
[0073] Table 2
[0074]
[0075]
[0076] According to Table 2 above, overexpression of ureA in Halomonas campaniensis LS21 can simultaneously achieve higher cell accumulation density, higher product content and lower ammonia emission.
[0077] Example 3
[0078] According to the same manner as in Example 1, ureA was overexpressed in Halomonas bluephagenesis WZY254, and the resulting engineered Halomonas was named Halomonas bluephagenesis WZY25-porin58-ureA.
[0079] Halomonas bluephagenesis WZY254 and Halomonas bluephagenesis WZY25-porin58-ureA were used to produce PHA by fermentation, and the cell dry weight, PHA content and ammonia concentration in the tail gas after fermentation are shown in Table 3 below.
[0080] Table 3
[0081] strains Cell dry weight PHA content Ammonia concentration in tail gas WZY254 98.31g / L 80% 0.3%(v / v) WZY254-porin58-ureA 102.16g / L 82% 0.02%(v / v)
[0082] According to Table 3 above, overexpression of ureA in Halomonas bluephagenesis WZY254 can simultaneously achieve higher cell accumulation density, higher product content and lower ammonia emission.
[0083] Comparative Example 1
[0084] UreA was overexpressed in Halomonas bluephagenesis WZY254 in substantially the same manner as in Example 1, except that the promoter used in this comparative example was the porin promoter numbered 203. The engineered Halomonas was named Halomonas bluephagenesis WZY25-porin203-ureA.
[0085] Halomonas bluephagenesis WZY254 and Halomonas bluephagenesis WZY25-porin58-ureA were used to produce PHA by fermentation, and the cell dry weight, PHA content and ammonia concentration in the tail gas after fermentation are shown in Table 3 below.
[0086] Table 4
[0087] strains Cell dry weight PHA content Ammonia concentration in tail gas WZY254 98.31g / L 80% 0.3%(v / v) WZY254-porin58-ureA 102.16g / L 82% 0.02%(v / v) WZY254-porin203-ureA 95.37g / L 75% 0.2%(v / v)
[0088] According to Table 4 above, the effect of overexpressing ureA in Halomonas bluephagenesis WZY254 using promoter No. 203 (porin203) is obviously not as good as that using promoter No. 58 (porin58).
[0089] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0090] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. An engineered Halomonas, characterized in that: In the engineered Halomonas, a first gene is overexpressed by a first promoter, wherein the first promoter is porin58, and the first gene is ureA.
2. The engineered Halomonas according to claim 1, characterized in that The nucleotide sequence of the first promoter is shown in SEQ ID: 1; Optionally, the nucleotide sequence of the first gene is shown as SEQ ID:
2.
3. The engineered Halomonas according to claim 1, characterized in that The Halomonas is selected from Halomonas bluephagenesis and / or Halomonas campaniensis; Optionally, the Halomonas is selected from the group consisting of Halomonas bluephagenesis TD01, Halomonas campaniensis LS21 and Halomonas bluephagenesis WZY254.
4. The engineered Halomonas according to claim 1, characterized in that The engineered Halomonas is Halomonas bluephagenesis TD01-porin58-ureA, Halomonas campaniensis LS21-porin58-ureA or Halomonas bluephagenesis WZY254-porin58-ureA.
5. A method for constructing an engineered Halomonas according to any one of claims 1 to 4, characterized in that: The method includes: overexpressing a first gene in Halomonas via a first promoter.
6. The method according to claim 5, characterized in that The step of causing the first gene in Halomonas to be overexpressed via the first promoter comprises: Inserting the first promoter and the first gene into a first vector to obtain a first plasmid; The first plasmid is transformed into the Halomonas by conjugation.
7. The method according to claim 6, characterized in that The first vector is pSEVA321.
8. A method for producing polyhydroxyalkanoate, characterized in that: The method comprises: fermenting and producing polyhydroxyalkanoates using the engineered Halomonas according to any one of claims 1 to 4; Optionally, the nitrogen source of the fermentation medium of the engineered Halomonas comprises urea.
9. The method according to claim 8, characterized in that The initial content of urea in the fermentation medium is 0.3 to 0.8 g / L, preferably 0.5 g / L.
10. The method according to claim 9, characterized in that The polyhydroxyalkanoate is selected from the group consisting of: 3-hydroxybutyric acid homopolymer PHB, 3-hydroxybutyric acid and 4-hydroxybutyric acid copolymer P3HB4HB, 3-hydroxybutyric acid, 4-hydroxybutyric acid and 3-hydroxyvaleric acid terpolymer PHBV4HB, 3-hydroxybutyric acid and 3-hydroxyhexanoic acid copolymer PHBHHx, 3-hydroxypropionic acid homopolymer, and 3-hydroxypropionic acid copolymer, The homopolymer of 3-hydroxypropionic acid is P3HP, and the copolymer of 3-hydroxypropionic acid is P(3HB-co-3HP) or PHBHP.
Citation Information
Cited By
Bacterial strain for synthesizing PHA by efficiently utilizing acetic acid and application of bacterial strain
CN120624325A
Strain for efficiently synthesizing pha from acetic acid and application thereof
CN120624325B
